Evidence questioning cromolyns effectiveness and selectivity as a mast cell stabilizer in mice

Laboratory Investigation

Volumn 92, Issue 10, 2012, Pages 1472-1482

  Oka, Tatsuya ^a   Kalesnikoff, Janet ^a   Starkl, Philipp ^a   Tsai, Mindy ^a   Galli, Stephen J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anaphylaxis; cromolyn; disodium cromoglycate; DSCG; mast cell; mouse; rat

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; CROMOGLYCATE DISODIUM; EVANS BLUE; HISTAMINE; IMMUNOGLOBULIN E; LIPOPOLYSACCHARIDE; MAST CELL PROTEASE 1; PROSTAGLANDIN D2; PROTEINASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; CCL2 PROTEIN, MOUSE; CHYMASE; DIAGNOSTIC AGENT; MCPT1 PROTEIN, MOUSE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EAR EDEMA; ENZYME RELEASE; EXTRAVASATION; FEMALE; HISTAMINE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAST CELL; MAST CELL DEGRANULATION; MEDIATOR RELEASE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PERITONEUM MAST CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; SPECIES DIFFERENCE; WILD TYPE; ANALYSIS OF VARIANCE; ANAPHYLAXIS; ANIMAL; BLOOD; C57BL MOUSE; CONTRAST MEDIUM EXTRAVASATION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; HUMAN; LEUKOCYTE; METABOLISM; PERITONEUM; SECRETION (PROCESS); TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANAPHYLAXIS; ANIMALS; ANTI-ASTHMATIC AGENTS; BETA-N-ACETYLHEXOSAMINIDASES; CHEMOKINE CCL2; CHYMASES; CROMOLYN SODIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; EVANS BLUE; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; HISTAMINE; HUMANS; IMMUNOGLOBULIN E; LEUKOCYTES; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PASSIVE CUTANEOUS ANAPHYLAXIS; PERITONEUM; RATS; SPECIES SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866849879     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.116     Document Type: Article

References (57)

1. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77: 1033-1079.
2. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008;9:1215-1223.
3. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010;10:440-452.
4. Tsai M, Grimbaldeston M, Galli SJ. Mast cells and immunoregulation/ immunomodulation. Adv Exp Med Biol 2011;716:186-211.
5. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012;18:693-704.
6. Akahoshi M, Song CH, Piliponsky AM, et al. Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. J Clin Invest 2011;121:4180-4191.
7. Metz M, Piliponsky AM, Chen CC, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 2006;313:526-530.
8. Piliponsky AM, Chen CC, Nishimura T, et al. Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med 2008;14:392-398.
9. Maurer M, Wedemeyer J, Metz M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004;432: 512-516.
10. Bernstein IL, Siegel SC, Brandon ML, et al. A controlled study of cromolyn sodium sponsored by the Drug Committee of the American Academy of Allergy. J Allergy Clin Immunol 1972;50:235-245.
11. Howell JB, Altounyan RE. A double-blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma. Lancet 1967;2:539-542.
12. Kusner EJ, Dubnick B, Herzig DJ. The inhibition by disodium cromoglycate in vitro of anaphylactically induced histamine release from rat peritoneal mast cells. J Pharmacol Exp Ther 1973;184:41-46.
13. Thomson DS, Evans DP. Inhibition of immediate hypersensitivity reactions by disodium cromoglycate. Clin Exp Immunol 1973;13:537-544.
14. Pearce FL, Befus AD, Gauldie J, et al. Mucosal mast cells. II. Effects of anti-allergic compounds on histamine secretion by isolated intestinal mast cells. J Immunol 1982;128:2481-2486.
15. Kobayashi K, Hiroi J, Kishi S, et al. Effects of quinotolast, a new orally active antiallergic drug, on experimental allergic models. Jpn J Pharmacol 1993;63:73-81.
16. Orr TS, Cox JS. Disodium cromoglycate, an inhibitor of mast cell degranulation and histamine release induced by phospholipase A. Nature 1969;223:197-198.
17. Storms W, Kaliner MA. Cromolyn sodium: fitting an old friend into current asthma treatment. J Asthma 2005;42:79-89.
18. Kobayashi Y, Okunishi H. Mast cells as a target of rheumatoid arthritis treatment. Jpn J Pharmacol 2002;90:7-11.
19. Huang M, Pang X, Karalis K, et al. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in apolipoprotein E knockout mice. Cardiovasc Res 2003;59:241-249.
20. Samoszuk M, Corwin MA. Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int J Cancer 2003; 107:159-163.
21. Bot I, de Jager SC, Zernecke A, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007;115:2516-2525.
22. Kneilling M, Hultner L, Pichler BJ, et al. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 2007;56:1806-1816.
23. Soucek L, Lawlor ER, Soto D, et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211-1218.
24. Costa R, Marotta DM, Manjavachi MN, et al. Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice. Br J Pharmacol 2008;154:1094-1103.
25. Nautiyal KM, Ribeiro AC, Pfaff DW, et al. Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci USA 2008;105:18053-18057.
26. Marques MJ, Ventura Machado R, Minatel E, et al. Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness. Muscle Nerve 2008;37:61-67.
27. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009;15:940-945.
28. Liao CH, Akazawa H, Tamagawa M, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 2010;120:242-253.
29. Sharma A, Abraham T, Sampaio A, et al. Sodium cromolyn reduces expression of CTGF, ADAMTS1, and TIMP3 and modulates post-injury patellar tendon morphology. J Orthop Res 2011;29: 678-683.
30. Braga F, Mota I. Homologous passive cutaneous anaphylaxis (PCA) in mice and heterologous PCA induced in rats with mouse IgE. Immunology 1976;30:655-669.
31. Marquardt DL, Walker LL, Wasserman SI. Cromolyn inhibition of mediator release in mast cells derived from mouse bone marrow. Am Rev Respir Dis 1986;133:1105-1109.
32. Forbes EE, Groschwitz K, Abonia JP, et al. IL-9-and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med 2008;205:897-913.
33. Komatsu H, Kojima M, Tsutsumi N, et al. Mechanism of inhibitory action of tranilast on the release of slow reacting substance of anaphylaxis (SRS-A) in vitro: effect of tranilast on the release of arachidonic acid and its metabolites. Jpn J Pharmacol 1988;46: 53-60.
34. Piliponsky AM, Chen CC, Grimbaldeston MA, et al. Mast cell-derived TNF can exacerbate mortality during severe bacterial infections in C57BL/6-KitW-sh/W-sh mice. Am J Pathol 2010;176:926-938.
35. Lilla JN, Chen CC, Mukai K, et al. Reduced mast cell and basophil numbers and function in Cpa3-Cre; Mcl-1fl/fl mice. Blood 2011;118: 6930-6938.
36. Oka T, Hori M, Ozaki H. Microtubule disruption suppresses allergic response through the inhibition of calcium influx in the mast cell degranulation pathway. J Immunol 2005;174:4584-4589.
37. Olivera A, Mizugishi K, Tikhonova A, et al. The sphingosine kinasesphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity 2007;26:287-297.
38. Wershil BK, Mekori YA, Murakami T, et al. 125I-fibrin deposition in IgE-dependent immediate hypersensitivity reactions in mouse skin. Demonstration of the role of mast cells using genetically mast cell-deficient mice locally reconstituted with cultured mast cells. J Immunol 1987;139:2605-2614.
39. Broide DH, Metcalfe DD, Wasserman SI. Functional and biochemical characterization of rat bone marrow derived mast cells. J Immunol 1988;141:4298-4305.
40. Wastling JM, Knight P, Ure J, et al. Histochemical and ultrastructural modification of mucosal mast cell granules in parasitized mice lacking the beta-chymase, mouse mast cell protease-1. Am J Pathol 1998; 153:491-504.
41. Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987;90:421-429.
42. Okayama Y, Benyon RC, Rees PH, et al. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1992;22:401-409.
43. Shichijo M, Inagaki N, Nakai N, et al. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy 1998;28:1228-1236.
44. Wang XS, Lau HY. Histamine release from human buffy coat-derived mast cells. Int Immunopharmacol 2007;7:541-546.
45. Okada M, Itoh H, Hatakeyama T, et al. Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J 2003;374:433-441.
46. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806-1818.
47. Okada M, Tokumitsu H, Kubota Y, et al. Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun 2002;292:1023-1030.
48. Yang Y, Lu JY, Wu X, et al. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 2010;86:1-5.
49. Freeman BC, Morimoto RI. The human cytosolic molecular chaperones hsp90, hsp70 (hsc70) and hdj-1 have distinct roles in recognition of a non-native protein and protein refolding. EMBO J 1996;15:2969-2979.
50. Wang G, Platt-Higgins A, Carroll J, et al. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 2006;66:1199-1207.
51. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8: 816-824.
52. Bertram J, Palfner K, Hiddemann W, et al. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcriptionpolymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 1998;9:311-317.
53. Wang J, Simonavicius N, Wu X, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006;281:22021-22028.
54. Furuta GT, Wang ZS, Wershil BK. Gastric inflammation during systemic anaphylaxis: neutrophil recruitment in stomach wall of mice does not require mast cell participation. Dig Dis Sci 1998;43: 2021-2027.
55. Ebihara N, Nishikawa M, Murakami A. Disodium cromoglycate inhibits capsaicin-induced eosinophil infiltration of conjunctiva independent of mast cells. Jpn J Ophthalmol 2006;50:205-210.
56. Kay AB, Walsh GM, Moqbel R, et al. Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. J Allergy Clin Immunol 1987;80:1-8.
57. Loh RK, Jabara HH, Geha RS. Disodium cromoglycate inhibits Sm-Se deletional switch recombination and IgE synthesis in human B cells. J Exp Med 1994;180:663-671.